메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting

TOKYO, Dec. 18, 2025 -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation data on the OhmX(™) platform at the Japanese Society of Human Genetics (JSHG) Annual Meeting taking place on December 17-20, 2025, in Yokohama, Japan. In partnership with Dr. Catherine Brownstein, M.P.H., Ph.D. from Boston Children's Hospital, Nabsys and HHT will host a luncheon seminar on Thursday, December 18, 2025 from 12:25-1:25 PM at the Yokohama Confer
- 김갑성 기자
- 2025-12-18 05:05
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets

TOKYO, Dec. 18, 2025 -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these challenging targets. Under
- 김갑성 기자
- 2025-12-18 00:00
Neutrinos Wins AI and Machine Learning Innovation Award at InsurInnovator Connect Vietnam 2025

Award recognizes Neutrinos' contribution to advancing AI adoption across the APAC region NEW YORK and SINGAPORE, Dec. 17, 2025 -- Neutrinos, a leader in AI-powered intelligent automation for insurers, has been recognized with the AI and Machine Learning Innovation Award at the IIC Vietnam Awards 2025. Held in conjunction with the annual InsurInnovator Connect Vietnam conference, the awards highlight innovations and initiatives that drive measurable progress and raise industry standards. Neutrinos received this recognition for its work in helping insurers operationalize
- 황정호 기자
- 2025-12-17 22:30
Datasea Advances Deployment of an Acoustics + AI-Driven Next-Generation Beauty & Health Intelligence System, Addressing a Multi-Billion-Dollar China Market Opportunity

BEIJING, Dec. 17, 2025 -- Datasea (Beijing) Technology Co., Ltd. ("Datasea"), a subsidiary of Datasea Inc. (NASDAQ: DTSS), today announced a strategic partnership with Shenzhen Yizhimei Technology Co., Ltd. ("Yizhimei"). Datasea will empower Yizhimei with its Acoustics + AI technologies to develop a next-generation Acoustics Digital AI Shampooing Robot and Beauty & Health Intelligence System, supporting the accelerated digital transformation of China's beauty and health industry. Leveraging Datasea's capabilities in acoustic high-tech innov
- 김갑성 기자
- 2025-12-17 22:30
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi-valent siRNA into clinical development. The Phase 1 trial is expected to begin dosing in Q1 2026. RN5681 is a GalNAc-conjugated, dual-targeting siRNA designed to simultaneously silence both PCSK9 and LPA, two genetically validated and complementary drivers of atherosclerotic cardiovascular disease. By unifying LDL
- 김갑성 기자
- 2025-12-17 21:00
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

SEOUL, South Korea, Dec. 17, 2025 -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity. MEDI&GENE's discovery platform is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects. Under the agreement, Lilly ExploR&D will bring Lilly's expertise in molecule
- 김갑성 기자
- 2025-12-17 21:00
GROWNSY Reaches 3 Million Households as Baby Care Brand Caps Breakthrough Year

[ 메디채널 김갑성 기자 ] Company credits parent feedback initiative and ISO 13485 medical-grade manufacturing standards for rapid growth NEW YORK, Dec. 17, 2025 -- Grownsy, a baby care products company specializing in creating innovative baby care products designed to fit seamlessly into modern family life., announced today that its products are now used in over 3 million households globally, marking a significant milestone in the company's strategic roadmap as they close out 2025. The growth follows a year in which GROWNSY implemented what it calls a "listener strategy" — s
- 김갑성 기자
- 2025-12-17 21:00
Bioptimus Unveils M-Optimus, a World Model for Biology

Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical innovation The Unveiling of M-Optimus: Bioptimus has trained its inaugural World Model for biology - a foundation model that learns interactions across multiple languages of biology - marking a revolutionary first step in simulating the full complexity of human life. Early Access to a Limited Number of Pioneer Clients: Bioptimus is now inviting a select number of partners to join this exclusive early-access phase. Accelerat
- 김갑성 기자
- 2025-12-17 20:00
Health on hold: Nearly 60% of Hongkongers surveyed delay medical care

Delays driven by family obligations and fear of becoming a burden highlight a growing health concern HONG KONG, Dec. 17, 2025 -- The findings of the study Patient Voices Hong Kong: How clarity, cost and choice shape care, a new Economist Impact report commissioned by Prudential plc, highlight the challenges faced by Hong Kong residents in accessing medical care and underscore their desire for clarity, support at every step, and seamless access to affordable medical services in Hong Kong. Healthcare services are accessible, timely support remains a challenge
- 김갑성 기자
- 2025-12-17 19:38
CUHK and MicroSigX partner to launch a breakthrough test aiding early autism diagnosis offering 200 free test quotas

HONG KONG, Dec. 17, 2025 -- The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) announced the official launch of the world's first "AI-Powered Multikingdom Microbial Biomarkers Technology" (MSX Metagenie®) today, in collaboration with MicroSigX Biotech Diagnostic Limited, a CUHK spin-off. This innovative technology detects risk of autism spectrum disorder (ASD) in children, enabling early intervention and support for at-risk families. In July 2024, the technology received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA),
- 김갑성 기자
- 2025-12-17 19:01

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분